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CpGs relieve arthritis
Arthritis sufferers might get some therapeutic relief from 
bacterial nucleic acids that usually goad on inflammation, if 
results from Wu et al. (page 1911) are any indication. Some 
of these short CpG repeats (CpGs) are now shown to prevent 
arthritis progression in a mouse model.
CpGs are well-known proinflammatory molecules that 
activate dendritic cells (DCs) via toll-like receptor (TLR)-9. The 
DCs then stimulate T cells and B cells. CpGs are therefore used in 
the clinic to enhance protection against infections and tumor 
development. But immune enhancement can be harmful if the 
response is directed against the host’s own antigens. CpGs and 
other TLR ligands, for example, further disease progression in 
many mouse arthritis models.
In some mouse models of allergy and asthma, however, CpGs 
exert a protective role. In these mice, CpG-activated DCs somehow 
jumpstart the proliferation of protective T cell subsets and stop B 
cells from secreting allergy-causing antibodies. Wu et al. wondered 
whether CpGs had a similar therapeutic effect on arthritis.
The team tested several known CpGs in mice that had 
developed arthritis in response to injected serum antibodies. 
Two structurally similar CpGs halted disease progression. Unlike 
disease-promoting CpGs, these helpful CpGs stimulated DCs to 
activate natural killer (NK) cells instead of T and B cells. The NK 
cells then produced interferon (IFN)-γ. This normally 
proinflammatory cytokine blocked neutrophil trafficking into the 
diseased joints, thereby lessening inflammation.
The authors attribute this disease-dampening effect to the 
fact that the T/B cell-mediated initiation phase had passed by 
the time the CpGs were delivered. The NK-mediated 
therapeutic effects may translate to human arthritis 
treatments, as T and B cells have usually already done their 
dirty work by the time patients arrive in the clinic. 
Liver-secreted inflammatory proteins 
and thickened arteries are two harbin-
gers of heart disease. Luchtefeld et al. 
(page  1935) now find a cause-and-
effect link between these risk factors. 
Their study shows that the pathway to 
inflammation amplifies plaque build-
up in the arteries.
Plaques are a consequence of high 
dietary cholesterol, which gloms onto 
arterial walls. Macrophages ingest the 
fat, die, and further harden the area 
into plaque. This condition, known as 
atherosclerosis, is associated with high 
levels of inflammatory cytokines such 
as interleukin (IL)-6. Liver cells acti-
vated by these cytokines release “acute 
phase” proteins (APPs), which are 
markers of heart disease.
When released during an immune 
response, however, APPs have an im-
mediate benefit. They trigger the com-
plement cascade and recruit macrophages 
to the inflamed areas. These events help 
clean up infection and injury—situations 
that require a strong, swift response. But 
APPs can cause a lot of damage if they 
are perpetually present, as seen in patients 
suffering from arthritis or lupus. These 
chronically inflamed individuals also 
suffer from atherosclerosis and are at 
high risk for heart failure.
Luchtefeld and colleagues now reveal 
the mechanism that links chronic inflam-
mation to heart disease: APPs seem to 
amplify plaques by attracting macrophages. 
The team inactivated the IL-6 receptor, 
gp130, in mice that are genetically pre-
disposed to atherosclerosis. The mice thus 
had fewer APPs. Even on a high choles-
terol diet, these animals had smaller 
plaques that contained fewer macrophages. 
Normally, cells in the plaque lure more 
macrophages by secreting the chemokine 
CCL2. But without APPs, this chemo-
kine was not produced.
The continuous triggering of gp130 
might also worsen cardiac health in 
humans. The authors tracked genetic 
variations in the human gp130 homo-
logue IL-6ST in families with a history 
of heart disease. They found that indi-
viduals who had developed coronary 
plaques carried the same IL-6ST allele. 
Screening for IL-6ST polymorphisms 
might thus allow for the early identifi-
cation of those who are predisposed to 
coronary artery disease. 
The accumulation of macrophages (red) 
in arterial plaques (top) is reduced by 
inactivating the IL-6 receptor gp130 (bottom).
The invasion (left) of neutrophils (red) into arthritic joints is 
prevented (right) by a CpG.
How inflammation signals heart trouble